XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements - Pfizer Enzyme Supply Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
Aug. 31, 2022
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenues           $ 70,143 $ 138,590 $ 104,754
Performance obligations satisfied     $ 17,937   $ 2,038      
Contract liabilities: deferred revenue     10,761   30,609 10,761 30,609  
Research and development revenue                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenues           27,237 21,914 34,097
Pfizer | Enzyme Product                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contract with customer, liability, retainer fee   $ 25,900            
Contract with customer, liability, retainer fee, creditable percentage   90.00%            
Contract with customer, liability, portion of retainer fee $ 23,300 $ 23,300            
Contract with customer, liability, retainer fee, non-creditable percentage 50.00%              
Performance obligations satisfied           8,200 75,400 $ 34,500
Contract liabilities: deferred revenue     $ 9,500   $ 24,400 $ 9,500 $ 24,400  
Pfizer | Enzyme Product | Revenue from Contract with Customer Benchmark | Customer Concentration Risk                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Concentration risk, percentage           12.00% 54.00% 33.00%
Pfizer | Research and development revenue                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenues       $ 5,000   $ 2,000